Benjamin Kogelmann

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Regulatory T Cells

Arabidopsis Thaliana

Staphylococcus Aureus

Top Venues

The New phytologist

Plant biotechnology journal

Proceedings of the National Academy of Sciences of the United States of America

Biotechnology journal

This page only lists publications with an associated author ORCID identifier.

Publications

Mamoona Khan, Simon Uhse, Janos Bindics, Benjamin Kogelmann, Nithya Nagarajan, Riaz Tabassum, Kishor D Ingole, Armin Djamei
Tip of the iceberg? Three novel TOPLESS-interacting effectors of the gall-inducing fungus Ustilago maydis. The New phytologist (2024)
Benjamin Kogelmann, Stanislav Melnik, Michaela Bogner, Somanath Kallolimath, Eva Stöger, Lin Sun, Richard Strasser, Marc-André D'Aoust, Pierre-Olivier Lavoie, Pooja Saxena, Johannes S Gach, Herta Steinkellner
A genome-edited N. benthamiana line for industrial-scale production of recombinant glycoproteins with targeted N-glycosylation. Biotechnology journal (2023)
Lukas Eidenberger, Benjamin Kogelmann, Herta Steinkellner
Plant-based biopharmaceutical engineering. Nature reviews bioengineering 1 (6) (2023)
Benjamin Kogelmann, Roman Palt, Daniel Maresch, Richard Strasser, Friedrich Altmann, Somanath Kallolimath, Lin Sun, Marc-André D'Aoust, Pierre-Olivier Lavoie, Pooja Saxena, Johannes S Gach, Herta Steinkellner
In planta expression of active bacterial GDP-6-deoxy-d-lyxo-4-hexulose reductase for glycan modulation. Plant biotechnology journal (2023)
Janos Bindics, Mamoona Khan, Simon Uhse, Benjamin Kogelmann, Laura Baggely, Daniel Reumann, Kishor D Ingole, Alexandra Stirnberg, Anna Rybecky, Martin Darino, Fernando Navarrete, Gunther Doehlemann, Armin Djamei
Many ways to TOPLESS - manipulation of plant auxin signalling by a cluster of fungal effectors. The New phytologist 236 (4) (2022)
Somanath Kallolimath, Lin Sun, Roman Palt, Karin Stiasny, Patrick Mayrhofer, Clemens Gruber, Benjamin Kogelmann, Qiang Chen, Herta Steinkellner
Highly active engineered IgG3 antibodies against SARS-CoV-2. Proceedings of the National Academy of Sciences of the United States of America 118 (42) (2021)